Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) on December 13, 2023. The filing details the results of the company's 2023 annual meeting of stockholders held on the same date. AgeX is an emerging growth company incorporated in Delaware with its principal executive offices in Alameda, California.
Key Financial Metrics
This filing is a corporate governance report and does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on voting outcomes and corporate actions.
Material Changes and Voting Results
Stockholders representing 82.36% of the outstanding common stock (31,255,819 shares) participated in the meeting. The following matters were voted upon:
- Election of Directors: Three nominees were elected: Gregory Bailey, Joanne Hackett, and Jean-Christophe Renondin. Significant broker non-votes occurred for all three candidates.
- Ratification of Auditors: Stockholders ratified the appointment of WithumSmith + Brown PC as the independent registered public accountants for the fiscal year ending December 31, 2023.
- Juvenescence Proposal: Stockholders approved a proposal permitting Juvenescence Limited to acquire additional AgeX common stock through the conversion of Series B Preferred Stock, even if this results in Juvenescence owning more than 19.9% of outstanding stock or 50% or more of the total outstanding shares.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to various risk factors detailed in AgeX's periodic SEC reports. No specific financial guidance or operational outlook was provided in this document.
Investor Verification Checklist
- Verify the correct registrant name is AgeX Therapeutics, Inc. (Ticker: AGE), not Serina Therapeutics.
- Review the implications of the approved "Juvenescence Proposal" regarding potential dilution and changes in ownership structure.
- Check the company's most recent 10-K or 10-Q for actual financial performance data, as this 8-K contains none.
- Confirm the tenure of the newly elected directors and their specific qualifications.